Free Trial

Gilead Sciences (GILD) Competitors

Gilead Sciences logo
$118.22 -0.27 (-0.22%)
As of 12:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GILD vs. AMGN, LGND, MRNA, REGN, VIR, VRTX, ABBV, MRK, PFE, and ALNY

Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Amgen (AMGN), Ligand Pharmaceuticals (LGND), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "medical" sector.

Gilead Sciences vs. Its Competitors

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.7%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 62.9% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$33.42B4.80$4.09B$12.2324.36
Gilead Sciences$28.75B5.10$480M$5.0223.55

Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Amgen presently has a consensus price target of $309.42, indicating a potential upside of 3.86%. Gilead Sciences has a consensus price target of $118.08, indicating a potential downside of 0.11%. Given Amgen's higher possible upside, equities analysts clearly believe Amgen is more favorable than Gilead Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
1 Sell rating(s)
11 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.35
Gilead Sciences
0 Sell rating(s)
6 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.86

Gilead Sciences has a net margin of 21.86% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen18.96% 174.71% 13.12%
Gilead Sciences 21.86%50.99%17.24%

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Amgen had 3 more articles in the media than Gilead Sciences. MarketBeat recorded 61 mentions for Amgen and 58 mentions for Gilead Sciences. Amgen's average media sentiment score of 1.34 beat Gilead Sciences' score of 1.17 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
47 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Gilead Sciences
41 Very Positive mention(s)
5 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Amgen beats Gilead Sciences on 12 of the 20 factors compared between the two stocks.

Get Gilead Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GILD vs. The Competition

MetricGilead SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$146.75B$3.40B$6.05B$10.50B
Dividend Yield2.67%2.30%5.73%4.80%
P/E Ratio23.5622.8585.1627.28
Price / Sales5.10269.65518.10200.08
Price / Cash17.2146.9537.5761.53
Price / Book7.6610.5412.406.82
Net Income$480M-$52.58M$3.32B$276.69M
7 Day Performance-0.03%0.57%0.52%0.18%
1 Month Performance5.04%15.45%10.05%8.18%
1 Year Performance37.75%17.98%75.51%34.82%

Gilead Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GILD
Gilead Sciences
4.8882 of 5 stars
$118.22
-0.2%
$118.08
-0.1%
+39.3%$146.75B$28.75B23.5617,600Positive News
AMGN
Amgen
4.5309 of 5 stars
$294.22
-1.2%
$309.70
+5.3%
-9.5%$158.29B$33.42B24.0428,000Positive News
Analyst Revision
LGND
Ligand Pharmaceuticals
4.0299 of 5 stars
$182.42
+0.8%
$176.50
-3.2%
+74.9%$3.58B$187.58M-45.7380
MRNA
Moderna
4.2692 of 5 stars
$27.53
-3.4%
$41.81
+51.9%
-54.5%$10.73B$3.24B-3.665,800
REGN
Regeneron Pharmaceuticals
4.764 of 5 stars
$584.70
-2.5%
$817.67
+39.8%
-43.5%$62.05B$14.21B14.7615,106Trending News
Analyst Forecast
Analyst Revision
VIR
Vir Biotechnology
3.3498 of 5 stars
$5.60
-2.3%
$17.30
+209.1%
-25.4%$780.04M$74.21M-1.40580News Coverage
Analyst Forecast
Insider Trade
VRTX
Vertex Pharmaceuticals
4.8352 of 5 stars
$402.98
-0.1%
$493.81
+22.5%
-15.0%$103.64B$11.02B28.896,100Positive News
Analyst Revision
ABBV
AbbVie
4.6428 of 5 stars
$230.25
-1.6%
$228.22
-0.9%
+17.0%$406.78B$56.33B109.6555,000Trending News
Analyst Forecast
Options Volume
Analyst Revision
MRK
Merck & Co., Inc.
4.9985 of 5 stars
$88.79
-0.5%
$106.41
+19.9%
-22.7%$221.86B$64.17B13.6975,000Trending News
Analyst Forecast
Analyst Revision
PFE
Pfizer
4.9768 of 5 stars
$26.45
-3.4%
$28.41
+7.4%
-15.7%$150.47B$63.83B14.0881,000Trending News
Dividend Announcement
Analyst Revision
ALNY
Alnylam Pharmaceuticals
4.0015 of 5 stars
$451.97
-1.0%
$448.04
-0.9%
+65.7%$59.33B$2.25B-183.252,230Analyst Downgrade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:GILD) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners